Press Releases
Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine A Bill & Melinda Gates Foundation grant will …
Osivax Appoints Dr. Chris Martin, Renowned Biotech Entrepreneur, to its Board of Directors Company honors Dr. Michael Watson for his significant impact …
Osivax Announces Last Patient Last Visit in Two Phase 2a Clinical Trials with Broad-Spectrum Influenza Vaccine Candidate OVX836 Lyon, France – December 21, …
Publications
Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
Leroux-Roels I, Waerlop G, Tourneur J, De Boever F, Maes C, Bruhwyler J, Guyon-Gellin D, Moris P, Del Campo J, Willems P, Leroux-Roels G, Le Vert A, Nicolas F.
April 2022. doi: 10.3389/fimmu.2022.852904
Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results.
Withanage K, De Coster I, Cools N, Viviani S, Tourneur J, Chevandier M, Lambiel M, Willems P, Le Vert A, Nicolas F, Van Damme P.
Oct. 2021. doi: 10.1093/infdis/jiab532
OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza.
Del Campo J, Bouley J, Chevandier M, Rousset C, Haller M, Indalecio A, Guyon-Gellin D, Le Vert A, Hill F, Djebali S, Leverrier Y, Marvel J, Combadière B and Nicolas F.
June 2021. doi: 10.3389/fimmu.2021.678483
OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.
Del Campo J, Pizzorno A, Djebali S, Bouley J, Haller M, Pérez-Vargas J, Lina B, Boivin G, Hamelin M-E, Nicolas F, Le Vert A, Leverrier Y, Rosa-Calatrava M, Marvel J, Hill F.
Jan. 2019. doi: 10.1038/s41541-019-0098-4.
Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine.
Zhao X, Yang F, Mariz F, Osen W, Bolchi A, Ottonello S, Müller M.
2020 Sep. e1008827. doi: 10.1371/journal.ppat.1008827
Minor capsid protein L2 polytope induces broad protection against oncogenic and mucosal human papillomaviruses.
Pouyanfard S, Spagnoli G, Bulli L, Balz K, Yang F, Odenwald C, Seitz H, Mariz FC, Bolchi A, Ottonello S, Müller M.
2018 Feb. J Virol 92:e01930-17. doi: 10.1128/JVI.01930-17.
Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles.
Spagnoli G, Pouyanfard S, Cavazzini D, Canali E, Maggi S, Tommasino M, Bolchi A, Müller M, Ottonello S.
Sci Rep. 2017; 7: 18000. Published online 2017 Dec 21. doi: 10.1038/s41598-017-18177-1.
SnoopLigase peptide-peptide conjugation enables modular vaccine assembly
Andersson AC, Buldun CM, Pattinson DJ, Draper SJ, Howarth M.Sci Rep.
2019 Mar 15;9(1):4625. doi: 10.1038/s41598-019-40985-w.
Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice.
Brod F, Miura K, Taylor I, Li Y, Marini A, Salman AM, Spencer AJ, Long CA, Biswas S.Front Immunol.
2018 Dec 4;9:2780. doi: 10.3389/fimmu.2018.02780.
Dual Plug-and-Display Synthetic Assembly Using Orthogonal Reactive Proteins for Twin Antigen Immunization.
Brune KD, Buldun CM, Li Y, Taylor IJ, Brod F, Biswas S, Howarth M.Bioconjug Chem.
2017 May 17;28(5):1544-1551. doi: 10.1021/acs.bioconjchem.7b00174.
A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice.
Tomusange K, Wijesundara D, Gummow J, Garrod T, Li Y, Gray L, Churchill M, Grubor-Bauk B, Gowans EJ.Sci Rep.
2016 Jun 30;6:29131. doi: 10.1038/srep29131.
Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
Li Y, Leneghan DB, Miura K, Brian IJ, Dicks MD, Fyfe AJ, Zakutansky SE, De Cassan S, Long CA, Draper SJ, Hill AV, Hill F, Biswas S. Sci Rep.
2016 January 8;6:18848. doi: 10.1038/srep18848.
T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein.
Forbes EK, de Cassan SC, Llewellyn D, Biswas S, Goodman AL, Cottingham MG, Long CA, Pleass RJ, Hill AV, Hill F, Simon J. Draper. PLoS ONE.
2012 September;7(9):e44943. doi:10.1371/journal.pone.0044943.
Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates.
Spencer AJ, Hill F, Honeycutt JD, Cottingham MG, Bregu M, Rollier CS, Furze J, Draper SJ, Søgaard KC, Gilbert SC, Wyllie DH, Hill AVS. PLoS ONE.
2012 March;7(3): e33555. doi:10.1371/journal.pone.0033555.
Immunocontraception in male feral swine treated with a recombinant gonadotropin-releasing hormone vaccine.
Campbell TA, Garcia MR, Miller LA, Ramirez MA, Long DB, Marchand JB, Hill F. JSHAP.
May 2010; 18(3):118-124.
The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria.
Ogun SA, Dumon-Seignovert L, Marchand JB, Holder AA, Hill F. Infect Immun.
2008 Aug;76(8):3817-3823. doi:10.1128/IAI.01369-07.
Effective induction of high-titer antibodies by viral vector vaccines.
Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, Hill F, Hill AV. Nat Med.
2008 Aug;14(8):819-821. doi: 10.1038/nm.1850.
Events
Barcelona – Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Development Update on OVX836 disruptive T-cell vaccin for broad-protection against multiple influenza strains”.
Belfast – Oral Presentation and Posters
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide preclinical results obtained with OVX033 as part of a presentation entitled “OVX033, T-cell based vaccine targeting the nucleocapsid provides broad-spectrum protection against SARS-COV-2 VoC in Hamster challenge model”. Two more posters entitled “Results of a phase 2 study with OVX836 suggest effectiveness in preventing Influenza-Like Illness and confirm good safety profile” and “How to drastically improve influenza prevention: the addition of a T-cell component to increase current vaccine efficacy, preclinical and early clinical results” are also presented.
Oxford – Oral Presentation
Alexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide latest clinical results obtained with OVX836 as part of a presentation entitled “Results of a phase 2 study with OVX836 suggest effectiveness in preventing Influenza-Like Illness and confirm good safety profile”.